Opioid Agonists and Antagonists

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to Lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

A patient with a history of opioid abuse requires long-term management. Considering the respiratory effects and potential for misuse, which of the following is the MOST appropriate strategy?

  • Switching to a combination of full MOR agonists, rotating between different drugs such as morphine, oxycodone, and fentanyl to prevent tolerance.
  • Prescribing high-dose methadone to ensure complete opioid receptor saturation and prevent cravings, while closely monitoring for adverse effects.
  • Initiating buprenorphine maintenance therapy, leveraging its partial agonist properties to reduce overdose risk and withdrawal symptoms. (correct)
  • Administering naloxone as a preventative measure, allowing the patient to self-administer upon experiencing any signs of respiratory depression.

In a clinical trial comparing buprenorphine and methadone for opioid use disorder treatment, which of the following outcomes would be MOST indicative of buprenorphine's safety advantage?

  • A significant reduction in self-reported cravings among patients receiving methadone compared to those on buprenorphine.
  • Comparable rates of relapse to opioid use in both groups, suggesting no significant difference in the efficacy of craving management.
  • Higher rates of treatment retention in the methadone group due to its stronger opioid effects and greater satisfaction among users.
  • A lower incidence of respiratory depression and overdose events in the buprenorphine group, despite similar rates of opioid use. (correct)

A patient is being transitioned from chronic high-dose opioid therapy involving a full MOR agonist to buprenorphine. What is the MOST critical consideration during this transition to prevent precipitated withdrawal?

  • Ensuring the patient has taken the full MOR agonist dose immediately before the first buprenorphine dose to minimize withdrawal symptoms.
  • Waiting until the patient is experiencing moderate withdrawal symptoms before administering the first dose of buprenorphine. (correct)
  • Initiating buprenorphine at a high dose to rapidly saturate opioid receptors and outcompete the remaining full MOR agonist.
  • Administering a full dose of naloxone prior to buprenorphine, to ensure all full MOR agonist are cleared from the receptors, making way for buprenorphine.

A patient who has overdosed on a full MOR agonist is admitted to the emergency department. After initial stabilization, the patient requires an opioid antagonist. Why is naloxone, rather than naltrexone, typically chosen in this acute setting?

<p>Naloxone has a faster onset of action and shorter duration compared to naltrexone, allowing for more controlled titration and observation for re-narcotization. (D)</p> Signup and view all the answers

A researcher is studying the effects of various opioids on receptor binding affinity and intrinsic activity. Which statement accurately compares a full MOR agonist (e.g., fentanyl) with a partial MOR agonist (e.g., buprenorphine)?

<p>Buprenorphine has higher binding affinity for the MOR than fentanyl, but lower intrinsic activity, resulting in a ceiling effect. (B)</p> Signup and view all the answers

A patient is prescribed naltrexone for alcohol use disorder, but also occasionally uses heroin. What is the MOST significant risk associated with this combination, and what should the patient be counseled about?

<p>The potential for severe and prolonged withdrawal symptoms if the patient attempts to overcome the naltrexone blockade with high doses of heroin. (A)</p> Signup and view all the answers

A toxicology report reveals the presence of both morphine and naloxone in a patient presenting with altered mental status. What does this combination suggest about the patient's condition?

<p>The patient is likely experiencing opioid withdrawal due to the naloxone reversing the effects of morphine. (B)</p> Signup and view all the answers

A patient with chronic pain is being considered for opioid therapy. Given the potential for tolerance and dependence, which of the following strategies is MOST crucial for responsible opioid prescribing?

<p>Implementing a comprehensive pain management plan that includes non-opioid analgesics, physical therapy, and psychological support. (C)</p> Signup and view all the answers

A research study is designed to evaluate the analgesic efficacy and respiratory effects of a novel opioid analogue compared to morphine. Which experimental parameter would be MOST indicative of the novel opioid's potential for causing respiratory depression?

<p>The shift in the carbon dioxide response curve, measuring the drug's impact on ventilatory drive and respiratory sensitivity. (A)</p> Signup and view all the answers

A patient with a history of heroin use presents to the clinic requesting medication-assisted treatment. They express a strong desire to avoid any medication that might cause them to feel a 'high.' Considering their concerns, which of the following would be the MOST appropriate initial approach?

<p>Initiate buprenorphine/naloxone, as the naloxone component is intended to deter misuse while buprenorphine addresses opioid cravings and withdrawal. (B)</p> Signup and view all the answers

A patient on long-term morphine for cancer pain develops severe opioid-induced constipation (OIC). Why is methylnaltrexone preferred over oral naltrexone for this patient?

<p>Methylnaltrexone is a peripherally-selective mu-opioid receptor antagonist, minimizing the risk of systemic opioid withdrawal and analgesia reversal, unlike naltrexone. (C)</p> Signup and view all the answers

A researcher is investigating the effects of a novel compound on opioid receptors. They observe that the compound binds to the mu-opioid receptor (MOR) with high affinity but elicits minimal downstream signaling. How would this compound be classified?

<p>Competitive MOR antagonist (B)</p> Signup and view all the answers

In a study comparing the efficacy of different opioid receptor subtypes in managing chronic neuropathic pain, researchers found that stimulating which receptor resulted in analgesia while minimizing the development of tolerance and dependence?

<p>Delta-opioid receptor (DOR) (C)</p> Signup and view all the answers

A patient with severe, chronic pain is being considered for long-term opioid therapy. The pain specialist is particularly concerned about the potential for opioid-induced hyperalgesia (OIH). Which strategy could be implemented to mitigate the risk of OIH?

<p>Rotating between different opioid agonists with varying receptor profiles to potentially reduce the sensitization of pain pathways. (B)</p> Signup and view all the answers

A researcher is developing a novel analgesic drug that selectively targets the delta-opioid receptor (DOR). What is the MOST significant advantage of targeting DOR over the mu-opioid receptor (MOR) for pain management?

<p>DOR activation is devoid of respiratory depression, constipation, and addiction liability, unlike MOR activation. (D)</p> Signup and view all the answers

A patient with a history of opioid use disorder is undergoing medication-assisted treatment with buprenorphine. They are also prescribed a medication that strongly induces the activity of CYP3A4 enzymes. What is the MOST significant concern regarding the interaction between buprenorphine and this CYP3A4 inducer?

<p>Reduced analgesic efficacy of buprenorphine due to decreased plasma concentrations. (D)</p> Signup and view all the answers

A patient is receiving chronic opioid therapy for severe back pain. Over time, the patient reports needing increasingly higher doses of the opioid to achieve adequate pain relief. What mechanism is MOST likely responsible for this phenomenon?

<p>Receptor desensitization and internalization due to chronic opioid exposure. (D)</p> Signup and view all the answers

A research team is investigating the signaling pathways activated by different opioid receptor subtypes. They discover that activation of a specific opioid receptor leads to a significant increase in the release of dopamine in the nucleus accumbens. Which opioid receptor is MOST likely responsible for this effect?

<p>Mu-opioid receptor (MOR) (A)</p> Signup and view all the answers

A patient presents to the emergency department with suspected opioid overdose. The patient is unresponsive with severely depressed respiration. After administering naloxone, the patient regains consciousness but becomes agitated and complains of severe pain. What is the MOST appropriate next step in managing this patient?

<p>Provide supportive care, including oxygen supplementation and pain management with non-opioid analgesics. (C)</p> Signup and view all the answers

A researcher is studying the effects of chronic opioid use on gene expression in the brain. They hypothesize that long-term opioid exposure alters the expression of genes involved in synaptic plasticity and reward pathways. Which advanced molecular technique would be MOST appropriate for testing this hypothesis?

<p>Next-generation sequencing (RNA-Seq) to analyze global gene expression patterns. (D)</p> Signup and view all the answers

Flashcards

Full MOR agonist

A substance that binds to the MOR receptor and produces a maximal response. Ex: Morphine, Heroin, Codeine, Oxycontin, Hydrocodone, Fentanyl, Methadone.

Methadone for opioid dependence

Medication option for treating opioiod dependence. It is a full MOR agonist.

Partial MOR agonist

A substance that binds to the MOR receptor but produces a submaximal response.

Buprenorphine safety

A partial MOR agonist that offers pain relief with a ceiling effect. Safer than methadone due to less respiratory depression

Signup and view all the flashcards

MOR Antagonists

Substances that bind to opioid receptors and block the effects of opioid agonists.

Signup and view all the flashcards

Examples of MOR antagonists

Examples include Naloxone and Naltrexone

Signup and view all the flashcards

Naltrexone for Morphine-Induced Constipation

Naltrexone doesn't cross the blood-brain barrier (BBB), inhibiting mu-opioid receptors (MORs) in the gut to alleviate constipation without affecting pain relief in the brain from morphine.

Signup and view all the flashcards

Opioid Receptors

The three main opioid receptors are Mu (MOR), Delta (DOR), and Kappa (KOR). MOR is the primary target for most current opioid analgesics.

Signup and view all the flashcards

Study Notes

  • A cancer patient using daily morphine infusions for a terminal illness has severe constipation side effects, prescribe naltrexone to treat.
  • Naltrexone does not cross the blood-brain barrier (BBB).
  • Naltrexone inhibits Mu Opioid Receptors (MORs) in the gut.
  • Inhibiting MORs in the gut helps with constipation.
  • Naltrexone assists with constipation without crossing the BBB, and without dampening the pain relieving effects of morphine in the brain.
  • The three opioid receptors are MOR, DOR, and KOR.
  • MOR is the main target for most of the current opioid analgesics.
  • Common full MOR agonists include:
    • Morphine
    • Heroin
    • Codeine
    • Oxycontin
    • Hydrocodone
    • Fentanyl
    • Methadone
  • Methadone is a good treatment option, as a full MOR agonist, for a patient presenting with a history of heroin abuse and opioid dependence.
  • Buprenorphine is a partial MOR agonist.
  • Buprenorphine is safer than methadone as it provides pain relief but has a ceiling effect, therefore it does not depress the patient's respiration as much as methadone would (methadone is a full agonist).
  • MOR antagonists include:
    • Naloxone
    • Naltrexone

Studying That Suits You

Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

Quiz Team

More Like This

opioids book questions
120 questions

opioids book questions

ThrivingSavannah9407 avatar
ThrivingSavannah9407
Opioid Agonist-Antagonists
18 questions
Mixed Opioid Agonist-Antagonists
10 questions
Use Quizgecko on...
Browser
Browser